These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34458008)

  • 1. A non-viral and selection-free
    Kocher T; Bischof J; Haas SA; March OP; Liemberger B; Hainzl S; Illmer J; Hoog A; Muigg K; Binder HM; Klausegger A; Strunk D; Bauer JW; Cathomen T; Koller U
    Mol Ther Nucleic Acids; 2021 Sep; 25():237-250. PubMed ID: 34458008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly Efficient Ex Vivo Correction of COL7A1 through Ribonucleoprotein-Based CRISPR/Cas9 and Homology-Directed Repair to Treat Recessive Dystrophic Epidermolysis Bullosa.
    Berthault C; Gaucher S; Gouin O; Schmitt A; Chen M; Woodley D; Titeux M; Hovnanian A; Izmiryan A
    J Invest Dermatol; 2024 Jun; 144(6):1322-1333.e13. PubMed ID: 38043638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ex Vivo COL7A1 Correction for Recessive Dystrophic Epidermolysis Bullosa Using CRISPR/Cas9 and Homology-Directed Repair.
    Izmiryan A; Ganier C; Bovolenta M; Schmitt A; Mavilio F; Hovnanian A
    Mol Ther Nucleic Acids; 2018 Sep; 12():554-567. PubMed ID: 30195791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Double-Nicking Strategies for COL7A1-Editing by Homologous Recombination.
    Kocher T; Wagner RN; Klausegger A; Guttmann-Gruber C; Hainzl S; Bauer JW; Reichelt J; Koller U
    Mol Ther Nucleic Acids; 2019 Dec; 18():496-507. PubMed ID: 31670199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly efficient CRISPR/Cas9-mediated exon skipping for recessive dystrophic epidermolysis bullosa.
    du Rand A; Hunt J; Samson C; Loef E; Malhi C; Meidinger S; Chen CJ; Nutsford A; Taylor J; Dunbar R; Purvis D; Feisst V; Sheppard H
    Bioeng Transl Med; 2024 Jul; 9(4):e10640. PubMed ID: 39036091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells.
    Jacków J; Guo Z; Hansen C; Abaci HE; Doucet YS; Shin JU; Hayashi R; DeLorenzo D; Kabata Y; Shinkuma S; Salas-Alanis JC; Christiano AM
    Proc Natl Acad Sci U S A; 2019 Dec; 116(52):26846-26852. PubMed ID: 31818947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COL7A1 Editing via CRISPR/Cas9 in Recessive Dystrophic Epidermolysis Bullosa.
    Hainzl S; Peking P; Kocher T; Murauer EM; Larcher F; Del Rio M; Duarte B; Steiner M; Klausegger A; Bauer JW; Reichelt J; Koller U
    Mol Ther; 2017 Nov; 25(11):2573-2584. PubMed ID: 28800953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs.
    Osborn MJ; Newby GA; McElroy AN; Knipping F; Nielsen SC; Riddle MJ; Xia L; Chen W; Eide CR; Webber BR; Wandall HH; Dabelsteen S; Blazar BR; Liu DR; Tolar J
    J Invest Dermatol; 2020 Feb; 140(2):338-347.e5. PubMed ID: 31437443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically Relevant Correction of Recessive Dystrophic Epidermolysis Bullosa by Dual sgRNA CRISPR/Cas9-Mediated Gene Editing.
    Bonafont J; Mencía Á; García M; Torres R; Rodríguez S; Carretero M; Chacón-Solano E; Modamio-Høybjør S; Marinas L; León C; Escamez MJ; Hausser I; Del Río M; Murillas R; Larcher F
    Mol Ther; 2019 May; 27(5):986-998. PubMed ID: 30930113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing.
    Bonafont J; Mencía A; Chacón-Solano E; Srifa W; Vaidyanathan S; Romano R; Garcia M; Hervás-Salcedo R; Ugalde L; Duarte B; Porteus MH; Del Rio M; Larcher F; Murillas R
    Mol Ther; 2021 Jun; 29(6):2008-2018. PubMed ID: 33609734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR-Cas9-based non-viral gene editing therapy for topical treatment of recessive dystrophic epidermolysis bullosa.
    Wang X; Wang X; Li Y; A S; Qiu B; Bushmalyova A; He Z; Wang W; Lara-Sáez I
    Mol Ther Methods Clin Dev; 2023 Dec; 31():101134. PubMed ID: 38027067
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Petković I; Bischof J; Kocher T; March OP; Liemberger B; Hainzl S; Strunk D; Raninger AM; Binder HM; Reichelt J; Guttmann-Gruber C; Wally V; Piñón Hofbauer J; Bauer JW; Koller U
    Front Med (Lausanne); 2022; 9():976604. PubMed ID: 36091706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictable CRISPR/Cas9-Mediated COL7A1 Reframing for Dystrophic Epidermolysis Bullosa.
    Kocher T; March OP; Bischof J; Liemberger B; Hainzl S; Klausegger A; Hoog A; Strunk D; Bauer JW; Koller U
    J Invest Dermatol; 2020 Oct; 140(10):1985-1993.e5. PubMed ID: 32142798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
    Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
    J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene Editing for the Efficient Correction of a Recurrent COL7A1 Mutation in Recessive Dystrophic Epidermolysis Bullosa Keratinocytes.
    Chamorro C; Mencía A; Almarza D; Duarte B; Büning H; Sallach J; Hausser I; Del Río M; Larcher F; Murillas R
    Mol Ther Nucleic Acids; 2016 Apr; 5(4):e307. PubMed ID: 27045209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytosine Deaminase Base Editing to Restore
    Naso G; Gkazi SA; Georgiadis C; Jayarajan V; Jacków J; Fleck R; Allison L; Ogunbiyi OK; McGrath JA; Ilic D; Di WL; Petrova A; Qasim W
    JID Innov; 2023 May; 3(3):100191. PubMed ID: 37213713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABE8e adenine base editor precisely and efficiently corrects a recurrent COL7A1 nonsense mutation.
    Sheriff A; Guri I; Zebrowska P; Llopis-Hernandez V; Brooks IR; Tekkela S; Subramaniam K; Gebrezgabher R; Naso G; Petrova A; Balon K; Onoufriadis A; Kujawa D; Kotulska M; Newby G; Łaczmański Ł; Liu DR; McGrath JA; Jacków J
    Sci Rep; 2022 Nov; 12(1):19643. PubMed ID: 36385635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical model for phenotypic correction of dystrophic epidermolysis bullosa by
    García M; Bonafont J; Martínez-Palacios J; Xu R; Turchiano G; Svensson S; Thrasher AJ; Larcher F; Del Rio M; Hernández-Alcoceba R; Garín MI; Mencía Á; Murillas R
    Mol Ther Methods Clin Dev; 2022 Dec; 27():96-108. PubMed ID: 36212909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa.
    Twaroski K; Eide C; Riddle MJ; Xia L; Lees CJ; Chen W; Mathews W; Keene DR; McGrath JA; Tolar J
    Br J Dermatol; 2019 Dec; 181(6):1247-1253. PubMed ID: 30924923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9-Mediated Generation of
    Alipour F; Ahmadraji M; Yektadoost E; Mohammadi P; Baharvand H; Basiri M
    Cell J; 2023 Oct; 25(10):665-673. PubMed ID: 37865875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.